Nature Scientific reports, Vol. 9, Issue 1, Pages 18793, 2019

PMID: 31827134

Epidermal growth factor receptor (EGFR) targeted therapies have shown limited efficacy in head and neck squamous cell carcinoma (HNSCC) patients despite its overexpression. Identifying molecular mechanisms associated with acquired resistance to EGFR-TKIs such as erlotinib remains an unmet need and a therapeutic challenge.

Read More

  https://www.ncbi.nlm.nih.gov/pubmed/31827134